Spyre Therapeutics Announces Topline Results From The Rheumatoid Arthritis Sub-Study Of The Skyway Phase 2 Trial Of Spy072
SYRE•Topline results from SKYWAY Phase 2 rheumatoid arthritis sub-study
Aug. 25 (Reuters) - Spyre Therapeutics Inc. SYRE.O:
- Spyre Therapeutics announces topline results from the rheumatoid arthritis sub-study of the SKYWAY Phase 2 trial of SPY072
- Spyre Therapeutics - SPY072 well tolerated with adverse event rates comparable to placebo
- Spyre Therapeutics - SPY072 shows statistically significant benefits versus placebo on multiple endpoints
- Spyre Therapeutics - topline data for SPY072 in PsA and axSpA expected Q4 2026
- Spyre Therapeutics Inc - magnitude of effect did not meet company's target to prioritize monotherapy development of SPY072 in rheumatoid arthritis
- Spyre Therapeutics Inc: SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028
